Allogene Therapeutics, Inc. (ALLO) Free Cash Flow by Year
Allogene Therapeutics, Inc. recorded an outflow of $149.6M in free cash flow in fiscal year 2025. This represents an increase of 25.6% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $102.6M in free cash flow. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Allogene Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ALLO Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
ALLO Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Allogene Therapeutics, Inc. financials
Frequently Asked Questions
What was Allogene Therapeutics, Inc.'s free cash flow in fiscal year 2025?
Allogene Therapeutics, Inc. recorded an outflow of $149.6M in free cash flow in fiscal year 2025.
How fast is Allogene Therapeutics, Inc.'s free cash flow growing?
Allogene Therapeutics, Inc. (ALLO) free cash flow rose by 25.6% year over year, from -$201.0M to -$149.6M in fiscal year 2025.
What is Allogene Therapeutics, Inc.'s free cash flow over the last twelve months?
Allogene Therapeutics, Inc. (ALLO) reported an outflow of $102.6M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Allogene Therapeutics, Inc.'s free cash flow changed over the years?
Across the 8 fiscal years this page covers, Allogene Therapeutics, Inc. (ALLO) free cash flow went from -$47.9M in fiscal year 2018 to -$149.6M in fiscal year 2025.
What was Allogene Therapeutics, Inc.'s free cash flow in the most recent quarter?
Allogene Therapeutics, Inc. (ALLO) reported -$32.1M in free cash flow in Q2 2026. This represents an increase of 17.7% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Allogene Therapeutics, Inc. (ALLO) reported on that line in every period on record.